27965 Cryosurgery as a novel treatment for Sweet syndrome: A case report

2021 ◽  
Vol 85 (3) ◽  
pp. AB169
Author(s):  
Jessica L. Jones ◽  
Jonathan Cleaver ◽  
David Cleaver ◽  
Nathan Cleaver ◽  
Lloyd Cleaver
2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Jintakorn Kuvatanasuchati ◽  
Karoon Leowsrisook

Abstract Background Chronic facial pain is a serious condition affecting millions of people worldwide. The reasons for chronic facial pain vary, and currently, the methods of treating chronic facial pain are expensive, invasive, and, based on current findings, ineffective. The purpose of this study is to develop and test an effective, cost-friendly method to treat patients with chronic facial pain. This study will examine the effectiveness of a novel treatment of a patient suffering from trigeminal neuralgia. Case presentation A 70-year-old Thai female visited the advanced general dentistry clinic at the Faculty of Dentistry, Mahidol University, Bangkok, Thailand. She was suffering from facial pain on her left side and was diagnosed by a physician as having trigeminal neuralgia. She experienced a sharp shooting pain that was triggered by facial movements such as chewing, speaking, or brushing teeth, and touching certain areas of her face. Bouts of pain lasted from a few seconds to several minutes, and episodes of several attacks lasted days, weeks, months, or longer prior to her visit to the advanced general dentistry clinic at Mahidol University. Physician designed an occlusal equilibration appliance for treating the patient by inserting the appliance in the mouth for dental occlusal equilibration (deprogram). The patient used this appliance by placing it in the mouth continuously (day and night) and removed it only when eating. After using the appliance for 2 weeks, the patient appeared to feel and look better prior to taking medication and was able to eat normally. The patient was pain free after treatment for a duration of 9 months. However, after 9 months, the pain reoccurred and manifested itself. Conclusion This novel treatment of recurrent facial pain showed an improvement of the patient’s chronic facial pain and serves as evidence to being a novel method for treating those suffering from trigeminal neuralgia.


2021 ◽  
Vol 9 ◽  
pp. 232470962199220
Author(s):  
Balraj Singh ◽  
Parminder Kaur ◽  
Michael Maroules

Immune checkpoint inhibitors have emerged as a novel treatment in a wide variety of malignancies; however, it is associated with a distinctive array of side effects known as immune-related adverse events. Hyperprogression is defined as an accelerated growth of disease burden in patients treated with immunotherapy. Limited literature is available regarding hyperprogression in hepatocellular cancer. We report a case of a 36-year-old male with no past medical history who presented with nausea, vomiting, and abdominal pain and was diagnosed with unresectable hepatocellular cancer and thereby started on atezolizumab and bevacizumab. The patient got only 1 cycle of treatment and unfortunately had hyperprogression of disease.


2015 ◽  
Vol 21 (7) ◽  
Author(s):  
Jonathan Miller ◽  
Nicole Lee ◽  
Naveed Sami
Keyword(s):  

Cureus ◽  
2021 ◽  
Author(s):  
Christos Sotiropoulos ◽  
Eftichia Sakka ◽  
Georgios J Theocharis ◽  
Konstantinos C Thomopoulos

Author(s):  
Monika Durak ◽  
Marek Tomala ◽  
Bartłomiej Nawrotek ◽  
Andrzej Machnik ◽  
Jacek Legutko

We report a patient with cardiogenic shock (CS) in the course of acute right ventricular myocardial infarction (MI). Our case highlights the use of continuous veno-venous hemofiltration as a novel treatment option for acute kidney injury in the setting of CS and the use of rotational_atherectomy in patients with MI.


2021 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Yong-Jun Du ◽  
Zhi-Yong Liu ◽  
Tian-Bao Huang ◽  
Jun-Jie Yu

2020 ◽  
Vol 4 (5) ◽  
pp. 815-818 ◽  
Author(s):  
Yazan Migdady ◽  
Asiri Ediriwickrema ◽  
Ryan Patrick Jackson ◽  
Wendy Kadi ◽  
Ridhi Gupta ◽  
...  

Key Points A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations. A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.


Sign in / Sign up

Export Citation Format

Share Document